SITE MAP | TERMS OF USE | © 2010 RHYTHM PHARMACEUTICALS
GASTROINTESTINAL FUNCTIONAL DISORDERS
Gastrointestinal (GI) functional and motility disorders are responsible for substantive morbidity and economic impact.
Gastroparesis affects up to 30% of the 24 million diabetics in the U.S. and causes chronic nausea, vomiting, malnutrition, and a high rate of hospitalization. The U.S. economic cost of gastroparesis is estimated to total $3.5 billion, and annual hospitalization costs for diabetic gastroparesis exceed $200 million.
Postoperative ileus (POI)—impaired GI motility following abdominal surgery—affects approximately 2.7 million surgical patients and is the leading cause of prolonged hospital stays, with an estimated annual cost of more than $750 million in the U.S.
Gastrointestinal (GI) functional and motility disorders are responsible for substantive morbidity and economic impact.
Gastroparesis affects up to 30% of the 24 million diabetics in the U.S. and causes chronic nausea, vomiting, malnutrition, and a high rate of hospitalization. The U.S. economic cost of gastroparesis is estimated to total $3.5 billion, and annual hospitalization costs for diabetic gastroparesis exceed $200 million.
Postoperative ileus (POI)—impaired GI motility following abdominal surgery—affects approximately 2.7 million surgical patients and is the leading cause of prolonged hospital stays, with an estimated annual cost of more than $750 million in the U.S.
